Page 47 - AN-3-3

Advanced Neurology TMAO and stroke

remodeling of the gut microbiota. mBio. 2016;7(2):e02210-15. doi: 10.1042/BSR20190515
doi: 10.1128/mBio.02210-15 59. Wu C, Li C, Zhao W, et al. Elevated trimethylamine N-oxide
55. Sharma V, Sharma V, Shahjouei S, et al. At the intersection related to ischemic brain lesions after carotid artery stenting.
of gut microbiome and stroke: A systematic review of the Neurology. 2018;90(15):e1283-e1290.
literature. Front Neurol. 2021;12:729399. doi: 10.1212/WNL.0000000000005298
doi: 10.3389/fneur.2021.729399 60. Liu D, Gu S, Zhou Z, Ma Z, Zuo H. Associations of plasma
56. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial TMAO and its precursors with stroke risk in the general
metabolism of phosphatidylcholine and cardiovascular risk. population: A nested case-control study. J Intern Med.
N Engl J Med. 2013;368(17):1575-1584. 2023;293(1):110-120.
doi: 10.1056/NEJMoa1109400 doi: 10.1111/joim.13572
57. Gupta N, Buffa JA, Roberts AB, et al. Targeted inhibition of 61. Wu C, Xue F, Lian Y, et al. Relationship between elevated
gut microbial trimethylamine N-oxide production reduces plasma trimethylamine N-oxide levels and increased stroke
renal tubulointerstitial fibrosis and functional impairment injury. Neurology. 2020;94(7):e667-e677.
in a murine model of chronic kidney disease. Arterioscler
Thromb Vasc Biol. 2020;40(5):1239-1255. doi: 10.1212/WNL.0000000000008862
doi: 10.1161/ATVBAHA.120.314139 62. Ma R, Fu W, Zhang J, Hu X, Yang J, Jiang H. TMAO:
A potential mediator of clopidogrel resistance. Sci Rep.
58. Rexidamu M, Li H, Jin H, Huang J. Serum levels of
trimethylamine-N-oxide in patients with ischemic stroke. 2021;11(1):6580.
Biosci Rep. 2019;39(6):BSR20190515. doi: 10.1038/s41598-021-85950-8

Volume 3 Issue 3 (2024) 9 doi: 10.36922/an.3005